The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
Banner University Medicine Lung Institute, Phoenix, Arizona, United States, 85006-2506
Southern Arizona VA Health Care System NAVREF PPDS, Tucson, Arizona, United States, 85723-0001
University of California, San Francisco-Fresno, Fresno, California, United States, 93701-2302
University of Southern California Keck School of Medicine, Los Angeles, California, United States, 90033-1036
UCLA Rheumatology, Los Angeles, California, United States, 90095-8344
University of California, San Francisco Medical Center, San Francisco, California, United States, 94143-2204
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Torrance, California, United States, 90502
Renstar Medical Research, Ocala, Florida, United States, 34470
Central Florida Pulmonary Group, PA, Orlando, Florida, United States, 32803
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 85 Years
ALL
No
Genentech, Inc.,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2027-08-10